# EXPRESS SCRIPTS FORMULARY ANALYSIS: 2025 → 2026


Generated: 2025-12-23 20:01:38
Mode: txt_extraction
Source: express_scripts_2025.pdf (22 pages)
        express_scripts_2026.pdf (22 pages)

--------------------------------------------------------------------------------

# Express Scripts Formulary Comparison: 2025 vs 2026

## Executive Summary

This analysis identifies significant formulary changes between the 2025 and 2026 Express Scripts National Preferred Formulary. Key themes include aggressive biosimilar adoption (particularly for adalimumab, ustekinumab, and tocilizumab), strategic brand exclusions, and expanded coverage in select therapeutic areas.

---

## 1. Drug Additions (New to 2026 Formulary)

### Cardiovascular
| Drug Name    | Category                        | Notes                                    |
| ------------ | ------------------------------- | ---------------------------------------- |
| OPSYNVI [SP] | Pulmonary Arterial Hypertension | New PAH combination therapy              |
| ENTRESTO     | Heart Failure                   | Implied addition (listed as alternative) |

### Central Nervous System
| Drug Name              | Category            | Notes                         |
| ---------------------- | ------------------- | ----------------------------- |
| INVEGA HAFYERA [INJ]   | Antipsychotic (LAI) | Long-acting injectable added  |
| INVEGA SUSTENNA [INJ]  | Antipsychotic (LAI) | Long-acting injectable added  |
| INVEGA TRINZA [INJ]    | Antipsychotic (LAI) | Long-acting injectable added  |
| INGREZZA [SP]          | Movement Disorders  | Tardive dyskinesia            |
| INGREZZA SPRINKLE [SP] | Movement Disorders  | New formulation               |
| pregabalin             | Anticonvulsant      | Generic now explicitly listed |
| atomoxetine            | ADHD                | Non-stimulant option added    |
| guanfacine ext-release | ADHD                | Non-stimulant option added    |

### Dermatology
| Drug Name | Category          | Notes                                       |
| --------- | ----------------- | ------------------------------------------- |
| VTAMA     | Atopic Dermatitis | Topical option (was only in psoriasis 2025) |

### Gastrointestinal
| Drug Name          | Category    | Notes            |
| ------------------ | ----------- | ---------------- |
| BARACLUDE SOLUTION | Hepatitis B | New HBV coverage |
| VEMLIDY            | Hepatitis B | New HBV coverage |

### Infectious Disease
| Drug Name           | Category   | Notes                            |
| ------------------- | ---------- | -------------------------------- |
| moxifloxacin (oral) | Antibiotic | Fluoroquinolone added            |
| linezolid           | Antibiotic | Implied as preferred alternative |

### Oncology
| Drug Name     | Category             | Notes                   |
| ------------- | -------------------- | ----------------------- |
| YONSA [SP]    | Prostate Cancer      | Abiraterone formulation |
| MEKINIST [SP] | Melanoma             | MEK inhibitor added     |
| RYDAPT [SP]   | Leukemia             | FLT3 inhibitor          |
| ERIVEDGE [SP] | Basal Cell Carcinoma | New indication coverage |
| ODOMZO [SP]   | Basal Cell Carcinoma | New indication coverage |
| VITRAKVI [SP] | NTRK+ Tumors         | Tumor-agnostic therapy  |
| STIVARGA [SP] | GI Cancers           | Multi-kinase inhibitor  |
| bortezomib    | Multiple Myeloma     | Generic implied         |

### Rheumatology/Immunology
| Drug Name                | Category       | Notes                        |
| ------------------------ | -------------- | ---------------------------- |
| AVSOLA [INJ] [SP]        | TNF Inhibitor  | Infliximab biosimilar added  |
| INFLIXIMAB [INJ] [SP]    | TNF Inhibitor  | Generic biosimilar added     |
| AVTOZMA IV [INJ] [SP]    | IL-6 Inhibitor | Tocilizumab biosimilar (NEW) |
| SIMPONI 100MG [INJ] [SP] | TNF Inhibitor  | For Ulcerative Colitis only  |
| VELSIPITY [SP]           | S1P Modulator  | New UC treatment             |
| OTEZLA XR [SP]           | PDE4 Inhibitor | Extended-release formulation |
| leflunomide              | DMARD          | Implied addition             |

### Specialty/Rare Disease
| Drug Name                        | Category              | Notes                 |
| -------------------------------- | --------------------- | --------------------- |
| ANDEMBRY AUTOINJECTOR [INJ] [SP] | Hereditary Angioedema | New HAE treatment     |
| STRENSIQ [INJ] [SP]              | Hypophosphatasia      | Rare disease addition |
| ARIKAYCE [SP]                    | Cystic Fibrosis       | Inhaled antibiotic    |

### Respiratory
| Drug Name             | Category               | Notes                  |
| --------------------- | ---------------------- | ---------------------- |
| TYVASO (non-DPI) [SP] | Pulmonary Hypertension | Additional formulation |

### Pain Management
| Drug Name                 | Category        | Notes                    |
| ------------------------- | --------------- | ------------------------ |
| ZTLIDO                    | Topical Pain    | Lidocaine patch brand    |
| KLOXXADO                  | Opioid Reversal | High-dose naloxone nasal |
| metaxalone (400mg, 800mg) | Muscle Relaxant | Explicit coverage        |

---

## 2. Drug Removals (Excluded in 2026)

### High-Impact Removals

#### Biologics - Major Brand Exclusions
| Drug Removed         | Category              | Preferred Alternative(s)                                               |
| -------------------- | --------------------- | ---------------------------------------------------------------------- |
| **HUMIRA**           | TNF Inhibitor         | ADALIMUMAB-ADAZ, ADALIMUMAB-ADBM, ADALIMUMAB-RYVK (Quallent), SIMLANDI |
| **STELARA SC**       | IL-12/23 Inhibitor    | IMULDOSA, SELARSDI, USTEKINUMAB-TTWE (Quallent), YESINTEK              |
| **STELARA IV**       | IL-12/23 Inhibitor    | Same as above                                                          |
| **ACTEMRA IV**       | IL-6 Inhibitor        | AVTOZMA IV, TYENNE                                                     |
| **ACTEMRA SC**       | IL-6 Inhibitor        | TYENNE SC                                                              |
| CYLTEZO              | Adalimumab Biosimilar | Other preferred biosimilars                                            |
| INFLECTRA [INJ] [SP] | Infliximab Biosimilar | AVSOLA, INFLIXIMAB generic                                             |

> ⚠️ **Critical Note:** STELARA SC exclusion effective **July 1, 2026** with continuation allowed through June 30, 2026

#### Additional Adalimumab Biosimilar Exclusions
| Drug Removed              | Manufacturer    |
| ------------------------- | --------------- |
| HADLIMA                   | Samsung Bioepis |
| HYRIMOZ                   | Sandoz          |
| AMJEVITA                  | Amgen           |
| ABRILADA                  | Pfizer          |
| ADALIMUMAB-AACF (IDACIO)  | Fresenius Kabi  |
| ADALIMUMAB-AATY (YUFLYMA) | Celltrion       |
| ADALIMUMAB-FKJP (HULIO)   | Mylan           |
| ADALIMUMAB-RYVK (by Teva) | Teva            |
| YUSIMRY                   | Coherus         |

#### Additional Ustekinumab Biosimilar Exclusions
| Drug Removed            | Notes                    |
| ----------------------- | ------------------------ |
| OTULFI                  | Biosimilar               |
| PYZCHIVA                | Biosimilar               |
| STEQEYMA                | Biosimilar               |
| WEZLANA                 | Biosimilar               |
| USTEKINUMAB (unbranded) | Non-preferred            |
| USTEKINUMAB-AEKN        | Non-preferred biosimilar |

#### Tocilizumab Exclusions
| Drug Removed | Notes               |
| ------------ | ------------------- |
| TOFIDENCE IV | Biosimilar excluded |

### CNS/Neurology Removals
| Drug Removed    | Category                        | Preferred Alternative(s)         |
| --------------- | ------------------------------- | -------------------------------- |
| AUSTEDO [SP]    | Huntington's/Tardive Dyskinesia | tetrabenazine, INGREZZA          |
| AUSTEDO XR [SP] | Huntington's/Tardive Dyskinesia | tetrabenazine, INGREZZA          |
| ERZOFRI [INJ]   | Antipsychotic (LAI)             | Other LAI antipsychotics         |
| BRIUMVI         | Multiple Sclerosis              | KESIMPTA, OCREVUS                |
| OXYCONTIN       | Opioid Analgesic                | Generic extended-release opioids |
| HYSINGLA ER     | Opioid Analgesic                | Generic extended-release opioids |

### Cardiovascular Removals
| Drug Removed             | Category      | Preferred Alternative(s)     |
| ------------------------ | ------------- | ---------------------------- |
| candesartan              | ARB           | Other generic ARBs           |
| FRAGMIN [INJ] [SP]       | Anticoagulant | enoxaparin, ELIQUIS, XARELTO |
| YUTREPIA [SP]            | PAH           | Other PAH agents             |
| TRACLEER SUSPENSION [SP] | PAH           | OPSUMIT, other PAH agents    |

### Diabetes Removals
| Drug Removed         | Category      | Preferred Alternative(s)        |
| -------------------- | ------------- | ------------------------------- |
| BYETTA [INJ]         | GLP-1 Agonist | OZEMPIC, TRULICITY, liraglutide |
| BYDUREON BCISE [INJ] | GLP-1 Agonist | OZEMPIC, TRULICITY, MOUNJARO    |

### Gastrointestinal Removals
| Drug Removed | Category          | Preferred Alternative(s)  |
| ------------ | ----------------- | ------------------------- |
| balsalazide  | IBD               | mesalamine, sulfasalazine |
| VIOKACE      | Pancreatic Enzyme | CREON, PANCREAZE, ZENPEP  |
| VIBERZI      | IBS-D             | Other IBS agents          |

### Dermatology Removals
| Drug Removed       | Category           | Preferred Alternative(s)  |
| ------------------ | ------------------ | ------------------------- |
| econazole          | Topical Antifungal | Other topical antifungals |
| tacrolimus topical | Atopic Dermatitis  | EUCRISA, VTAMA, biologics |

### Oncology Removals
| Drug Removed   | Category         | Preferred Alternative(s)       |
| -------------- | ---------------- | ------------------------------ |
| imatinib [SP]  | CML              | dasatinib, BOSULIF, SCEMBLIX   |
| IMBRUVICA [SP] | CLL/Lymphoma     | CALQUENCE, BRUKINSA            |
| ALUNBRIG [SP]  | Lung Cancer      | ALECENSA, other ALK inhibitors |
| LORBRENA [SP]  | Lung Cancer      | Other ALK inhibitors           |
| REVLIMID [SP]  | Multiple Myeloma | Other MM agents                |
| DARZALEX [SP]  | Multiple Myeloma | Other MM agents                |
| KYPROLIS [SP]  | Multiple Myeloma | bortezomib, NINLARO            |

### Specialty/Rare Disease Removals
| Drug Removed      | Category                | Preferred Alternative(s)     |
| ----------------- | ----------------------- | ---------------------------- |
| ALYFTREK [SP]     | Cystic Fibrosis         | Other CF modulators          |
| RADICAVA ORS [SP] | ALS                     | No direct alternative listed |
| HEMGENIX [SP]     | Hemophilia Gene Therapy | Factor products, HEMLIBRA    |

### Ophthalmic Removals
| Drug Removed       | Category            | Preferred Alternative(s)     |
| ------------------ | ------------------- | ---------------------------- |
| RESTASIS MULTIDOSE | Dry Eye             | cyclosporine generic, XIIDRA |
| XDEMVY [SP]        | Demodex Blepharitis | Not specified                |
| EYSUVIS            | Dry Eye             | Other dry eye agents         |

### Women's Health Removals
| Drug Removed                                | Category      | Preferred Alternative(s)       |
| ------------------------------------------- | ------------- | ------------------------------ |
| ethinyl estradiol/drospirenone/levomefolate | Contraceptive | ethinyl estradiol/drospirenone |
| ethinyl estradiol/ethynodiol                | Contraceptive | Other combination OCs          |

### Miscellaneous Removals
| Drug Removed       | Category               | Preferred Alternative(s) |
| ------------------ | ---------------------- | ------------------------ |
| rasagiline         | Parkinson's Disease    | Other MAO-B inhibitors   |
| SAVELLA            | Fibromyalgia           | duloxetine, other SNRIs  |
| DYSPORT [INJ] [SP] | Botulinum Toxin        | MYOBLOC                  |
| GRASTEK            | Allergen Immunotherapy | Other immunotherapy      |
| RAGWITEK           | Allergen Immunotherapy | Other immunotherapy      |

---

## 3. Tier Changes

> **Note:** Explicit tier assignments are not provided in either formulary document. The following are inferred changes based on positioning and preferred status.

### Likely Tier Improvements (Lower Cost Tier)
| Drug               | 2025 Status           | 2026 Status          | Rationale             |
| ------------------ | --------------------- | -------------------- | --------------------- |
| pregabalin         | Not explicitly listed | Explicitly covered   | Generic availability  |
| INGREZZA           | Not listed            | Preferred [SP]       | Replaces AUSTEDO      |
| AVSOLA             | Not listed            | Preferred biosimilar | New infliximab option |
| INFLIXIMAB generic | Not listed            | Preferred            | Biosimilar addition   |

### Likely Tier Demotions (Higher Cost Tier)
| Drug      | 2025 Status          | 2026 Status | Rationale                          |
| --------- | -------------------- | ----------- | ---------------------------------- |
| CYLTEZO   | Preferred biosimilar | Excluded    | Consolidation to fewer biosimilars |
| INFLECTRA | Preferred biosimilar | Excluded    | Replaced by AVSOLA/generic         |

---

## 4. Restriction Changes

### New Prior Authorization Requirements

| Drug/Category           | New PA Requirement   | Notes                                      |
| ----------------------- | -------------------- | ------------------------------------------ |
| APOKYN                  | Conditional coverage | "Under certain conditions" for Parkinson's |
| DUVYZAT                 | Conditional coverage | For Duchenne Muscular Dystrophy            |
| RUKOBIA ER              | Conditional coverage | Heavily treatment-experienced HIV patients |
| PALFORZIA               | Conditional coverage | Peanut allergy treatment                   |
| ZELSUVMI                | Conditional coverage | Molluscum contagiosum                      |
| Various oncology agents | Conditional coverage | Expanded clinical criteria                 |

### New Step Therapy Requirements

| Drug                    | Step Therapy Requirement                                 | Notes                 |
| ----------------------- | -------------------------------------------------------- | --------------------- |
| VYEPTI                  | Must try AIMOVIG, AJOVY, or EMGALITY first               | Migraine prevention   |
| BOTOX (migraine)        | Must try AIMOVIG, AJOVY, EMGALITY, or QULIPTA first      | NEW in 2026           |
| BRIUMVI                 | Must try preferred MS agents                             | Before approval       |
| Non-preferred MS agents | Trial of dimethyl fumarate, fingolimod, or teriflunomide | Clarified requirement |

### Removed/Modified Restrictions

| Drug       | 2025 Restriction | 2026 Change                   |
| ---------- | ---------------- | ----------------------------- |
| STELARA SC | Standard PA      | Excluded (effective 7/1/2026) |
| ACTEMRA    | Standard PA      | Excluded - use biosimilars    |

### Inflammatory Conditions Program (IACCV) - Enhanced

**2026 Preferred First-Line Agents:**
- ADALIMUMAB-ADAZ
- ADALIMUMAB-ADBM (by Boehringer Ingelheim & Quallent)
- ADALIMUMAB-RYVK (by Quallent)
- ENBREL
- SIMLANDI
- AVSOLA (NEW)
- INFLIXIMAB generic (NEW)
- IMULDOSA (NEW - ustekinumab)
- SELARSDI (NEW - ustekinumab)
- USTEKINUMAB-TTWE by Quallent (NEW)
- YESINTEK (NEW - ustekinumab)
- AVTOZMA IV (NEW - tocilizumab)
- TYENNE (NEW - tocilizumab)

---

## 5. Biosimilar/Generic Substitution Changes

### Major Biosimilar Transitions

#### Adalimumab (Humira) Biosimilar Strategy
| 2025 Preferred             | 2026 Preferred             | 2026 Excluded      |
| -------------------------- | -------------------------- | ------------------ |
| ADALIMUMAB-ADAZ            | ADALIMUMAB-ADAZ            | HUMIRA             |
| ADALIMUMAB-ADBM            | ADALIMUMAB-ADBM            | CYLTEZO            |
| ADALIMUMAB-RYVK (Quallent) | ADALIMUMAB-RYVK (Quallent) | HADLIMA, HYRIMOZ   |
| CYLTEZO                    | SIMLANDI                   | AMJEVITA, ABRILADA |
| SIMLANDI                   | -------------------------- | Multiple others    |

#### Ustekinumab (Stelara) Biosimilar Strategy - NEW for 2026
| 2025 Status     | 2026 Preferred              | 2026 Excluded         |
| --------------- | --------------------------- | --------------------- |
| STELARA covered | IMULDOSA                    | STELARA (eff. 7/1/26) |
| --------------- | SELARSDI                    | OTULFI                |
| --------------- | USTEKINUMAB-TTWE (Quallent) | PYZCHIVA              |
| --------------- | YESINTEK                    | STEQEYMA, WEZLANA     |

#### Tocilizumab (Actemra) Biosimilar Strategy - NEW for 2026
| 2025 Status     | 2026 Preferred     | 2026 Excluded |
| --------------- | ------------------ | ------------- |
| ACTEMRA covered | AVTOZMA IV         | ACTEMRA IV    |
| --------------- | TYENNE (IV and SC) | ACTEMRA SC    |
| --------------- | ------------------ | TOFIDENCE IV  |

#### Infliximab Biosimilar Strategy
| 2025 Preferred | 2026 Preferred     | 2026 Excluded |
| -------------- | ------------------ | ------------- |
| INFLECTRA      | AVSOLA             | INFLECTRA     |
| -------------- | INFLIXIMAB generic | REMICADE      |
| -------------- | ------------------ | RENFLEXIS     |

### New Generic Preferences
| Brand           | Generic Alternative                       | Category           |
| --------------- | ----------------------------------------- | ------------------ |
| AUSTEDO         | tetrabenazine                             | Movement Disorders |
| OXYCONTIN       | morphine sulfate ER, generic oxycodone ER | Pain               |
| BYETTA/BYDUREON | liraglutide                               | GLP-1 Agonist      |

---

## 6. Therapeutic Class Coverage Shifts

### Expanded Coverage Areas

#### Hepatitis B
- **2025:** Limited coverage
- **2026:** Added BARACLUDE SOLUTION, VEMLIDY
- **Impact:** Improved HBV treatment options

#### Movement Disorders
- **2025:** AUSTEDO preferred
- **2026:** INGREZZA now preferred; AUSTEDO excluded
- **Impact:** Shift to valbenazine from deutetrabenazine

#### Long-Acting Injectable Antipsychotics
- **2025:** Limited paliperidone options
- **2026:** Full INVEGA LAI portfolio (HAFYERA, SUSTENNA, TRINZA)
- **Impact:** Expanded schizophrenia treatment options

#### Oncology - Basal Cell Carcinoma
- **2025:** Not explicitly covered
- **2026:** ERIVEDGE, ODOMZO added
- **Impact:** New hedgehog pathway inhibitor coverage

### Reduced Coverage Areas

#### Multiple Myeloma
- **2025:** REVLIMID, DARZALEX, KYPROLIS, POMALYST, NINLARO
- **2026:** POMALYST, NINLARO, bortezomib (implied)
- **Impact:** Significant reduction in branded MM options

#### Chronic Lymphocytic Leukemia
- **2025:** IMBRUVICA, CALQUENCE, BRUKINSA
- **2026:** CALQUENCE, BRUKINSA (IMBRUVICA excluded)
- **Impact:** BTK inhibitor consolidation

#### Cystic Fibrosis
- **2025:** ALYFTREK, KITABIS PAK, TOBI PODHALER
- **2026:** ARIKAYCE, KITABIS PAK, TOBI PODHALER
- **Impact:** CFTR modulator changes

### Biosimilar-Driven Class Restructuring

#### Inflammatory Conditions (RA, PsA, PsO, IBD, etc.)
| Mechanism              | 2025 Approach                 | 2026 Approach                             |
| ---------------------- | ----------------------------- | ----------------------------------------- |
| TNF-α (adalimumab)     | Multiple biosimilars + HUMIRA | Consolidated to 4 preferred biosimilars   |
| TNF-α (infliximab)     | INFLECTRA preferred           | AVSOLA + generic preferred                |
| IL-12/23 (ustekinumab) | STELARA preferred             | 4 biosimilars preferred; STELARA excluded |
| IL-6 (tocilizumab)     | ACTEMRA preferred             | AVTOZMA + TYENNE preferred                |

---

## 7. Summary Tables

### High-Impact Changes Summary

| Change Type              | Count | Key Examples                                    |
| ------------------------ | ----- | ----------------------------------------------- |
| Major Brand Exclusions   | 15+   | HUMIRA, STELARA, ACTEMRA, AUSTEDO, IMBRUVICA    |
| Biosimilar Additions     | 10+   | AVSOLA, AVTOZMA, IMULDOSA, SELARSDI, YESINTEK   |
| New Drug Additions       | 20+   | INVEGA LAIs, INGREZZA, VEMLIDY, oncology agents |
| Therapeutic Class Shifts | 5     | Movement disorders, MM, CLL, inflammatory       |

### Cost Impact Projections

| Category                | Expected Direction | Rationale                       |
| ----------------------- | ------------------ | ------------------------------- |
| Inflammatory Conditions | ↓ Decrease         | Biosimilar mandates             |
| Oncology                | ↔ Mixed            | Some exclusions, some additions |
| Diabetes                | ↔ Stable           | Minimal changes                 |
| CNS                     | ↔ Mixed            | AUSTEDO→INGREZZA; new LAIs      |
| Specialty Overall       | ↓ Decrease         | Aggressive biosimilar adoption  |

### Member Transition Requirements

| Current Drug | Action Required                     | Deadline        |
| ------------ | ----------------------------------- | --------------- |
| HUMIRA       | Switch to preferred biosimilar      | January 1, 2026 |
| STELARA SC   | Switch to preferred biosimilar      | July 1, 2026    |
| ACTEMRA      | Switch to AVTOZMA or TYENNE         | January 1, 2026 |
| AUSTEDO      | Switch to INGREZZA or tetrabenazine | January 1, 2026 |
| IMBRUVICA    | Switch to CALQUENCE or BRUKINSA     | January 1, 2026 |
| INFLECTRA    | Switch to AVSOLA or generic         | January 1, 2026 |

---

## 8. Recommendations for Plan Sponsors

1. **Member Communication:** Prioritize outreach for HUMIRA, STELARA, and ACTEMRA users given large affected populations

2. **Transition Support:** Implement clinical support programs for biosimilar transitions, especially for complex inflammatory conditions

3. **STELARA Timeline:** Note the delayed exclusion date (7/1/2026) - plan communications accordingly

4. **Oncology Review:** Evaluate impact of MM and CLL drug exclusions on specialty spend and member access

5. **Movement Disorder Patients:** Coordinate AUSTEDO to INGREZZA transitions with neurology providers

6. **Monitor Biosimilar Performance:** Track clinical outcomes and member satisfaction with new biosimilar preferences